source
- Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial resultsBraveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…
- Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectationsMedicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…